[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Roger Strair\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100652272","early-phase-1-a-pilot-study-of-soursop-tea-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-aml-or-multiple-myeloma-mm-100652272",false,"NCT07771803","A Pilot Study of Soursop Tea in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)","Soursop","Inclusion Criteria:\n\n* Patients with relapsed or refractory AML or MM not on any anti-neoplastic therapy who have exhausted all therapies and have no available therapy.\n* For AML: Quantifiable leukemia cells in blood (patients without circulating AML blasts may participate if they agree to baseline and post-treatment bone marrow testing)\n* For MM: Quantifiable M component (SPEP) or serum free light chain abnormality (ratio greater than 10)\n* ECOG PS 0,1, or 2\n* ALT, AST less than 3 times ULN\n* Bilirubin (total) \\\u003C 2.5 mg\u002FdL\n* Renal function - estimated GFR \\> 40 ml\u002Fmin\n* No uncontrolled\u002Factive infections\n* Negative pregnancy test if of childbearing potential\n* No chronic neurologic disorders (peripheral neuropathy \\> grade 2; Parkinson's disease; Alzheimer's disease; other neurologic diseases will be discussed with the PI)\n\nExclusion Criteria:\n\n* Inability to understand the study procedures\n* Inability to understand the consent form --Pregnancy, breastfeeding, or inability or unwillingness to use effective contraception","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Purpose\u002FSpecific Aims\n\nThe study will determine if there is a reduction in malignant cell burden when patients with relapsed and\u002For refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop).\n\nThe study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed\u002Frefractory AML or MM for whom there are no standard therapeutic options.",[26,27],"AML (Acute Myeloid Leukemia)","Multiple Myeloma Refractory",[29],"relapsed\u002Frefractory","RECRUITING","2026-08-14",{"date":33,"type":34},"2026-08-18","ACTUAL",{"date":36,"type":34},"2025-06-30",{"date":38,"type":20},"2026-12-30",{"name":40,"class":41},"Roger Strair","OTHER",""]